Rezera, formerly NodThera, filed for an initial public offering to fund its decade-long NLRP3 program focused on peripheral artery disease. The filing underscores continued investor appetite for inflammatory-target franchises, but also highlights the capital intensity and long lead times typical for pathway-driven drug development without clear late-stage readouts in the public summary. For industry watchers, the IPO filing is a near-term financing signal: expect increased scrutiny on trial design, biomarker strategy, and the pathway from inflammation target biology to registrational endpoints.